BioAge Labs, Inc. (NASDAQ:BIOA) Receives $43.50 Consensus Price Target from Analysts

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have been given an average rating of “Moderate Buy” by the seven brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $43.50.

A number of equities research analysts have recently issued reports on BIOA shares. Needham & Company LLC assumed coverage on shares of BioAge Labs in a research note on Friday, March 27th. They issued a “buy” rating and a $50.00 target price on the stock. BTIG Research assumed coverage on BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Roth Capital began coverage on BioAge Labs in a research note on Wednesday, May 27th. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th.

BioAge Labs Price Performance

BIOA opened at $22.32 on Friday. The stock has a market capitalization of $992.12 million, a PE ratio of -9.30 and a beta of 0.61. The firm’s fifty day moving average price is $19.96 and its 200 day moving average price is $19.11. BioAge Labs has a 12-month low of $4.11 and a 12-month high of $25.95.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The firm had revenue of $2.77 million for the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. On average, equities research analysts forecast that BioAge Labs will post -2.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

Several institutional investors and hedge funds have recently made changes to their positions in BIOA. Janus Henderson Group PLC boosted its holdings in BioAge Labs by 411.8% in the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after purchasing an additional 1,685,063 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of BioAge Labs in the 4th quarter worth about $13,892,000. Stempoint Capital LP acquired a new position in shares of BioAge Labs in the 1st quarter valued at about $5,923,000. Millennium Management LLC boosted its holdings in shares of BioAge Labs by 749.8% in the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after buying an additional 270,479 shares during the period. Finally, Sphera Funds Management LTD. bought a new stake in shares of BioAge Labs during the 4th quarter valued at about $3,215,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.